January 22, 2024

Employer Impact Report: Weight Loss Drugs: Cutting Through the Noise on GLP-1s

Indianapolis, IN – January 22, 2024 – Apex Benefits Group is proud to announce the Employer Impact Report on Weight Loss Drugs, a three-session webinar series designed to provide employers with clarity and answers as they navigate the impacts of obesity and the growing tsunami of GLP-1s.

As employers strive to fight back increasing health care costs, the increasing prevalence of obesity has become a significant cost driver. Are GLP-1s a miracle cure? Or are they a long-term cost crisis? Opinions about, but clarity is lacking. This webinar series tackles these challenges head-on, delivering actionable insights and practical strategies to help employers build a sustainable response to obesity and weight loss drugs.

“The intersection of obesity and weight loss drugs is a complex and rapidly evolving issue, with significant implications for employees’ health as well as employer benefit plans,” says Jim Harenberg, chief operating officer at Apex Benefits Group. “This webinar series cuts through the noise and empowers employers with the knowledge and tools they need to make informed decisions that benefit both their bottom line and their employees’ overall well-being.

Why This Series is Critical Now

  • Obesity rates are at an all-time high, impacting nearly half of all American adults and contributing to a cascade of chronic health conditions such as diabetes, heart disease and cancer.
  • Weight loss drug spending is exploding, with GLP-1s alone projected to be in use by 9% of the U.S. population by 2030. These drugs, while potentially effective, carry hefty price tags that strain employer healthcare budgets.
  • Workplace culture surrounding weight and weight loss can be fraught with bias and discrimination, further complicating the issue for employers seeking to address obesity in a sensitive and effective manner.

About the Series: A Three-Part Approach

The “Employer Impact Report: Weight Loss Drugs” Webinar Series is designed to guide employers through the fog surrounding the issue — simplifying the complexities, providing clear answers to pressing questions and giving leaders the foundation for a response to the growing demand for GLP-1s.

Session 1: Weigh Your Options (February 7, 2024) – This session delves into the history of obesity and weight loss treatment in America. Then explore the pros and cons of the three main approaches employers can take to address the issue.

Session 2: Explore the Landscape (March 6, 2024) – Led by pharmacists and pharmacy industry experts, this session dives deep into the world of GLP-1s. Examine their efficacy, potential side effects, and cost implications. Employers will gain insights into the evolving landscape of weight loss drugs and how to safeguard their future.

Session 3: Chart Your Course (April 3, 2024) – This final session focuses on navigating the compliance and workplace culture challenges associated with obesity and weight loss drugs. Participants will learn best practices for creating a weight-inclusive workplace, mitigating bias, and implementing their response to GLP-1s in a sustainable manner.

Registration and Additional Information

Registration for the “Employer Impact Report: Weight Loss Drugs” Webinar Series is now open. To save your seat and learn more, please visit https://apexbg.com/employer-impact-weight-loss-drugs/.

About Apex Benefits:

Apex Benefits is Indiana’s largest employee benefits broker and consulting firm dedicated exclusively to delivering group insurance plans that save employers money and reduce risk. Our team of clinicians, analysts and benefits strategists have the experience to contain health care expenses, reduce pharmacy spend and improve employee well-being. For more than 20 years, Apex has proven to be a long-term partner that does the heavy lifting to make sure Indiana employers don’t pay more than they should for their benefits.

Media Contact

Margaret Osborn, Vice President of Marketing Communications